Ms. Sarah Crowley-Ikenberry is the Associate Director for Stakeholder Engagement and Clinical Outcomes at the Office of Therapeutic Biologics and Biosimilars (OTBB) in the U.S. Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research (CDER). She leads OTBB’s stakeholder engagement and education program, and FDA’s activities related to biosimilars communication activities. This includes providing communication advice and support to senior leaders and the agency about communicating strategic priorities, initiatives, and educational information about biosimilar and interchangeable products. Ms. Crowley-Ikenberry received her Master of Arts in Communication from Johns Hopkins University.